Growing royalty anchors Neuren first ever dividend program

Key points

• Neuren declares a fully franked interim dividend for H1 2026
• Dividend is anchored to growing royalty income from DAYBUE
• H1 2026 royalty income up 29% to US$23 million
• Neuren's balance sheet remains strong with A$287 million cash and short-term investments

Full summary

Neuren Pharmaceuticals (ASX: NEU) announced its first-ever dividend program, declaring a fully franked interim dividend for H1 2026, anchored to its growing royalty income from DAYBUE (trofinetide). The interim dividend for H1 2026 is 15 cents per share, representing 90% of the Available Pool of A$21.1 million. Neuren's H1 2026 royalty income increased by 29% to US$23 million. The company's balance sheet remains strong with A$287 million in cash and short-term investments. Neuren's exclusive global licensee, Acadia Pharmaceuticals, increased its full-year 2026 global net sales guidance for DAYBUE to US$480-510 million. The European Commission granted marketing authorization for DAYBUE in the EU, with a commercial launch anticipated in Germany in early Q4 2026. Neuren is also developing NNZ-2591 (ercanetide) for multiple neurodevelopmental disorders, with ongoing clinical trials for Phelan-McDermid syndrome and Pitt Hopkins syndrome.

Guidance

H1 2026 royalty income up 29% to US$23 million, full-year 2026 guidance US$480-510 million

Outlook

Neuren anticipates continued growth in royalty income and maintains a strong balance sheet, with ongoing clinical trials for NNZ-2591.